COMMUNIQUÉS West-GlobeNewswire

Les données positives de l’essai de phase 2a de Bioxodes montrent le fort potentiel de son candidat médicament innovant BIOX-101 dans l’AVC hémorragique
11/09/2025
Le critère de sécurité a été atteint et des signes encourageants d’efficacité ont été observés lors de l’essai mené auprès de 23 patients touchés par un AVC hémorragique Les résultats suggèrent que BIOX-101 réduit le [...]
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
11/09/2025
Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH) Findings suggest BIOX-101 reduced hematoma volume and slowed perihematomal edema growth [...]
Bioptimus Assembles Elite Scientific Advisory Board to Build Next-Gen AI Models for Biology
11/09/2025
Eight internationally renowned experts join Bioptimus to pioneer large-scale foundation models that will transform science and medicine PARIS, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Bioptimus, the pioneering start-up [...]
Communiqué de presse : Le SAR402663 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de la dégénérescence maculaire liée à l’âge néovasculaire
11/09/2025
Le SAR402663 de Sanofi a obtenu la désignation « fast track » aux États-Unis pour le traitement de la dégénérescence maculaire liée à l’âge néovasculaire Désignation obtenue pour une thérapie génique intravitréenne [...]
Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
11/09/2025
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal gene therapy with the potential to eliminate treatment burden for [...]
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
11/09/2025
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody ® and Moditope ® active immunotherapies to treat cancer, today announces a business update [...]
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering
11/09/2025
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial public offering of 19,000,000 shares of its common stock at a public offering [...]
Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma
10/09/2025
Long-term follow-up data for daraxonrasib monotherapy in second line metastatic pancreatic ductal adenocarcinoma reinforces promising clinical activity and durability Highly encouraging initial clinical results for [...]
LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions
10/09/2025
BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has made an [...]
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
10/09/2025
DUBLIN, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of [...]
electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
10/09/2025
ROCKAWAY, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Andy Brown has joined [...]
Keystone Place at Newbury Brook Senior Living Community Expands with 39 New Apartments, Launches Innovative Transitional Memory Care.
10/09/2025
TORRINGTON, CT , Sept. 10, 2025 (GLOBE NEWSWIRE) -- In response to the growing demands for senior living apartments, Keystone Place at Newbury Brook in Torrington Connecticut has completed a brand-new addition of 39 [...]
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/09/2025
SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
10/09/2025
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company’s previous Phase 2b challenge study - SOUTH SAN FRANCISCO, Calif., [...]
Cytek Biosciences Brings Full Spectrum Cell Analysis to Leading Clinical Global Conferences ICCS and ESCCA
10/09/2025
Spectral Flow Cytometry Pioneer Unveils Innovations Accelerating Efficiency and Discovery FREMONT, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- With cancer research and diagnostics driving the need for deeper, faster [...]
Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray
10/09/2025
WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve ® Antimicrobial Wound Gel and Spray U.S [...]
Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
10/09/2025
The First Precision Oncology Trial to Use a Functional Proteomics and Phosphoproteomics Assay for Treatment Decision Making in a Pan-Tumor Study Golden, CO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a [...]
Design Therapeutics Appoints Justin Gover to Board of Directors
10/09/2025
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the [...]
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/09/2025
PALO ALTO, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that the [...]

Pages